Skip to main content
. 2014 Dec;21(6):e748–e759. doi: 10.3747/co.21.1899

FIGURE 1.

FIGURE 1

Probabilistic sensitivity analyses of cost-effectiveness and acceptability curves for pazopanib versus placebo (A,B) from the health care system perspective and (C,D) from the societal perspective, using the partitioned-survival model and assuming unequal post-progression survival and post-treatment anticancer therapy costs for pazopanib and placebo. qalys = quality-adjusted life-years.